Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Sideris Pharmaceuticals
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Subject has iron-overload secondary to β-thalassemia requiring chronic red blood cell transfusions and iron chelation therapy
Subject weighs ≥35 kg
Subject is willing to discontinue current iron chelation therapy at least 7 days prior to the first dose of SP-420 and for the duration of the study
Serum ferritin ≥700 ng/mL and iron saturation ≥70% within 3 weeks before Baseline (Day 1)
Cardiac T2\* score \>20 msec within 6 months before Baseline (Day 1)
Willing to use contraception during the study
You may not be if
Pregnant or breast-feeding
Serum creatinine greater than the upper limit of normal
Platelet count \<100 × 10\^9/L
Use of another investigational drug within the last 30 days
Significant cardiac, renal, hepatic dysfunction or other clinically significant conditions that, in the opinion of the Investigator, would exclude the subject
